This pre-announcement represents, what I consider to be, a significant departure from prior financial reports. Typically, management at NVO provides any guidance increases concurrent with the release of a financial report. This notification has taken place prior to the fiscal release.
Will Wegovy become the next pharmaceutical brand that is considered “buzz-worthy”? It appears possible.